ATRX and neoplasm: Our research has not completely elucidated how ATRX protein expression alters ETS transcription factor activity, but the enrichment of the ETS binding motifs with changes in chromatin accessibility suggest that functional ATRX may repress these transcription factors by maintaining closed chromatin, effectively preventing the tumor-promoting sequelae that would otherwise occur with active ETS protein binding.